Table 2. Alpha-diversity metrics for IBD subtype, disease activity, 6-MP use (Median (range)).
| Reads per sample | Coverage (%) | Observed OTUs | Chao1 | Shannon | |
| CD | 8,053.5 | 97,4 | 477.2 | 684.0 | 6.6 |
| (6,503.0–10,033.0) | (94.8–99.3) | (72.1–652.8) | (99.7–1087.6) | (1.4–7.1) | |
| UC | 8,097.0 | 97.0 | 499.3 | 753.4 | 6.7 |
| (6,194–11,030) | (95.8–98.6) | (272.7–675.7) | (433.1–1047.3) | (5.5–7.7) | |
| Exacerbation | 7,921.0 | 97.4 | 493.3 | 726.3 | 6.7 |
| (6,194.0–11,030.0) | (95.8–99.3) | (72.1–664.5) | (99.7–1087.6) | (1.4–7.7) | |
| Remission | 8,169.0 | 97.0 | 493.9 | 747.7 | 6.6 |
| (6,503.0–10,013.0) | (94.8–99.1) | (160.6–675.7) | (308.9–1067.3) | (2.8–7.4) | |
| Thiopurine use | 8,193.0 | 97.8 | 338.9 | 489.3 | 5.8 |
| (6,465.0–10,013.0) | (96.2–99.3) | (72.1–517.4)a | (99.7–868.4)a | (1.4–7.0)b | |
| No thiopurine use | 7,929.0 | 96.6 | 569.4 | 875.9 | 6.7 |
| (6,194.0–11,030.0) | (94.8–98.0) | (406.9–675.7) | (605.9–1087.6) | (5.8–7.7) |
a
significantly lower in thiopurine users, p<0.001.
b
significantly lower in thiopurine users, p<0.01.